This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"At a time when most Americans are demanding long overdue changes in federal cannabis policy, Acting DEA Administrator Derek Maltz epitomizes the failed policies and approaches of the past. The post Career Drug Warrior Named Acting DEA Administrator appeared first on NORML.
"In these comments ANA agrees with the analysis that cannabis has numerous therapeutic qualities and should be moved to Schedule III. Further, ANA urges the Department of Justice and Drug Enforcement Administration to act expeditiously to have cannabis decontrolled under the CSA.""ANA
According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report , the agency and its law enforcement partners confiscated an estimated four million marijuana plants in 2019 – up from 2.8 It was the second-lowest number of arrests reported by the DEA in the past decade.
In light of the Drug Enforcement Administration’s (DEA) announcement to schedule a hearing on the rescheduling of cannabis, Americans for Safe Access (ASA) emphasizes the urgent need for compassionate leadership in Congress to advocate for the rights of medical cannabis patients.
NORML's Deputy Director Paul Armentano said that he was disappointed but hardly surprised by the DEA's decision to disproportionately include groups opposed to marijuana policy reform as designated participants. The post DEA Judge Pushes Back Timeline for In-Person Testimony in Marijuana Rescheduling Hearing appeared first on NORML.
According to a DEA memorandum , the agency requested to expand its policing powers beyond the enforcement of federal drug laws to include the enforcement of “any federal crime committed as a result of protests over the death of George Floyd.” The DEA possesses the power to strictly enforce these violations of law.
.” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. Read NORML’s new op-ed, “Three years ago the DEA said they would remove roadblocks to cannabis research — they still haven’t, here.).
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
The post DEA Reports More Marijuana Seizures, Fewer Arrests in 2022 appeared first on NORML. Federal law enforcement agents and their partners seized nearly 5.7 million cultivated marijuana plants in 2022. This is the highest annual seizure total reported by the agency since 2011.
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. What could the implications be for patients on their medical cannabis journey? Rescheduling would stand to have the largest impact on cannabis research and business taxes.
Federal agents seized fewer total marijuana plants in 2018, but made more arrests for cannabis-related offenses, according to annual data compiled by the US Drug Enforcement Administration. Adult-use retail sales of cannabis began in California in 2018. million marijuana plants nationwide in 2018. million in 2017 to 1.4
Watch as we explore the significance of the last 12 years in establishing cannabis' "currently accepted medical use" and learn why this matters! Watch as we explore the significance of the last 12 years in establishing cannabis' "currently accepted medical use" and learn why this matters!
Hello, real-world high-quality cannabis. The post DEA finally ends fed monopoly on schwaggy research-grade cannabis appeared first on Leafly. Goodbye, Mississippi ditch weed.
The DEA's five-part test to determine 'currently accepted medical use' is flawed, say the plaintiffs. The post New lawsuit aims to force DEA to reschedule marijuana appeared first on Leafly.
The Drug Enforcement Administration wants to increase the amount of cannabis and psychedelics it researches in 2023. The post DEA wants to boost production of cannabis and psychedelics research in 2023? appeared first on Leafly.
DEA Potential Reclassification of Marijuana Policy. In recent discussions surrounding drug policy reform, the reclassification of marijuana by the Drug Enforcement Administration (DEA) has emerged as a pivotal issue. Read More
For the second time in four years, the US Drug Enforcement Administration is proposing regulatory changes to procedures governing the federally licensed manufacture of cannabis for clinical research purposes. The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants.
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
When we started Americans for Access, we were facing paramilitary style raids from the DEA, only 8 states had passed laws creating criminal exemptions for medical cannabis patients, the DEA was still saying that cannabis was a gateway drug and there was no legal access anywhere!
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.
Two days before a federal court deadline, the DEA says it will do what it said it would do three years ago. The post DEA Says It Will Finally Let Others Grow Research-Grade Cannabis appeared first on Leafly.
The post DEA Asks Court To Overturn Cannabis Rescheduling Appeal first appeared on Cannabis Law Report. Drug Enforcement Administration reiterated that a lawsuit challenging marijuana’s classification as a Schedule 1 drug under the federal Controlled Substances Act should be … Read More.
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis. Shutterstock).
Sixty-three percent of respondents also agreed, “The DEA should reclassify marijuana so that it is no longer a schedule I drug.". The post Survey: Majority of Health Care Professionals Endorse Cannabis Use Instead of Opioids in Chronic Pain Patients appeared first on NORML.
The post Wasn’t the DEA Going to Let Others Grow Research-Grade Cannabis? Yes, it was. So why has the agency delayed applications? Sue Sisley demands an answer, and the courts agree with her. appeared first on Leafly.
Drug Enforcement Administration (DEA) has proposed dramatically raised levels of legal cannabis and psychedelic production in 2022 for use in studies. After already increasing production quotas for 2021, the DEA is calling for a 60% increase in marijuana production. million grams, according to reporting by Marijuana Moment.
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.
The language is general but it looks like the DEA will be trying to nip supply in the bud at source. WASHINGTON – The Drug Enforcement Administration today announced a comprehensive review of DEA’s international operations and foreign footprint, including administrative and financial support for those operations from DEA headquarters.
One Arizona church, known as the Church of the Eagle and the Condor (CEC), recently settled a lawsuit with the Drug Enforcement Agency (DEA), the Department of Homeland Security (DHS), and other federal agencies. The DEA will also take samples of shipments to ensure that the only substance entering the country is ayahuasca.
A vague memory tells us that the DEA were looking for a contractor early 2019 ? The post DEA - We're Still Burnin' Weed first appeared on Cannabis Law Report. What happened to the last contractor. Marijuana Moment has … Read More.
The 2019 end-of-year report finds that the number of federal defendants charged with cannabis-associated crimes declined by 28 percent. Separate data reported by the US Drug Enforcement Administration in July reported a decline in DEA-led marijuana seizures, but showed an increase in DEA arrests for marijuana violations in 2018.
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. Since then many different parties have tried to reschedule or end prohibition by filing petitions with DEA per the CSA protocol on rescheduling. That one was granted.
who wishes to legally study the health effects of cannabis have been limited since 1968 to a single legal supplier of the drug. This action by the DEA means researchers will be able to study marijuana from more than one grower. There’s no question it is a problem for just one supplier to have a monopoly on studying cannabis.
13 by the San Diego/Imperial Counties Joint Labor Management Cannabis Committee made up of representatives of UFCW Local 135 , and local companies March & Ash and Embarc. What’s more, synthesized Delta-9 THC is present in many of these products, despite being prohibited in both California’s cannabis and hemp programs.
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. Click here to send a message to your Representative and urge them to support the measure. . The agency ultimately rejected her decision.
As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?
The lawsuit—filed last year by cannabis researcher Sue Sisley of the Scottsdale Research Institute, the Battlefield Foundation and veterans Lorenzo Sullivan and Gary Hess— received oral arguments in June and largely centers on DEA’s 2020 denial of a one-page marijuana rescheduling petition filed by a separate individual.
Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.
SUMMARY: The Drug Enforcement Administration (DEA) is amending its regulations to facilitate the cultivation of … Read More. The post Document – DEA: Controls To Enhance the Cultivation of Marihuana for Research in the United States first appeared on Cannabis Law Report. ACTION: Final rule.
Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. .”
Marijuana Moment The Drug Enforcement Administration (DEA) is weighing in on the legal status of lesser known cannabinoids such as THCA, delta-8 THC and hydrogenated CBD.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content